Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a novel anti-TSLP bispecific antibody (GR2002) in healthy Chinese adults: a randomized, placebo-controlled phase 1 trial. (PubMed, Eur J Pharm Sci) - Jan 11, 2026 - "Single-dose subcutaneous administration of GR2002 demonstrated favorable safety and tolerability, linear PK, and low immunogenicity. These findings warrant the subsequent clinical development of STSA-1002."
Clinical • Journal • P1 data • PK/PD data • Infectious Disease • Respiratory Diseases • TSLP
|
|
Chongyou Lee; Fan Huang; Fang Men; Haifeng Song; Jiaojiao Zhang; Liming Chen; Qian Wang; Qingshan Zheng; Qun Gu; Rui Ding; Shuang Li; Suping Niu; Wei Wang; Wenyan Zhao; Yanting Li; Yi Fang; Yian Liu; Ziyan Ding
|